A Phase I Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytical Treatment Interruption in HIV-Living Participants Who Initiated ART During Acute/Early HIV-1 Infection.

 

Key Inclusion Criteria:

1. Have a Laboratory Diagnosis of Acute HIV Infection;

2. Have initiated ART within 90 days of the diagnosis of acute HIV infection;

3. Have not stopped using ART for more than 14 consecutive days;

4. Have been on ART for at least one year since initiation;

5. Have had an undetectable HIV viral load since initial viral suppression under ART and for at least one year.

​

Status: Expected Start Date: Second Half of 2026.